Introduction {#s1}
============

Offspring of mothers with preexisting or gestational diabetes mellitus (GDM) are at risk for higher birth weight (BW) and adiposity as well as childhood metabolic disorders, including obesity, impaired glucose tolerance, and dyslipidemia ([@B1]--[@B3]). Mechanisms underlying these risks are not well defined but likely relate to fetal overnutrition in the setting of available maternal fuels ([@B2],[@B3]).

One fuel present in increased supply in GDM is glucose. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study, a population-based study of \>23,000 women conducted from 2000 to 2006, and others demonstrated a linear relationship between maternal glucose and offspring BW and fatness ([@B2],[@B4]). This is likely mediated through glucose-stimulated insulin secretion in the fetus. Additional fuels also likely contribute ([@B5]). For example, pregnant women with GDM have increased circulating triglycerides in the third trimester. Maternal free fatty acids, which are derived from triglycerides, cross the placenta, serve as substrates for triglyceride synthesis, and contribute to fetal growth ([@B2],[@B3],[@B6]). Amino acids in maternal fasting plasma have been correlated with BW among women with diet-controlled GDM ([@B7]). The role of these and other fuels in risks associated with maternal hyperglycemia is unknown. To address possible metabolic linkages between maternal hyperglycemia and offspring phenotypes, we performed targeted and nontargeted metabolomics together with pathway, network, and random forest analyses in 400 European ancestry HAPO mothers.

Research Design and Methods {#s2}
===========================

Participants {#s3}
------------

We studied 400 HAPO Caucasian mother-offspring dyads of northern European ancestry from Belfast, U.K., and Brisbane and Newcastle, Australia, field centers ([Table 1](#T1){ref-type="table"}). Dyads were sampled so that maternal glucose and BMI, newborn BW, and sum of skinfolds (SS) spanned the range observed in HAPO ([@B4]).

###### 

Demographics of mothers and their offspring

  -------------------------------------- ------------------
  Field center, *N* (%)                  
   Belfast, U.K.                         188 (47.0)
   Brisbane, Australia                   136 (34.0)
   Newcastle, Australia                  76 (19.0)
  Maternal parity, *N* (%)               
   First child                           203 (50.7)
   Second or third child                 197 (49.2)
  Newborn sex, *N* (%)                   
   Male                                  209 (52.2)
   Female                                191 (47.8)
  Maternal characteristics               
   Age at OGTT (years)                   29.4 (5.12)
   BMI at OGTT (kg/m^2^)                 29.0 (4.89)
   Mean arterial pressure (mmHg)         83.1 (6.89)
   FPG (mg/dL)                           82.1 (6.14)
   One-hour plasma glucose (mg/dL)       131.7 (27.24)
   Two-hour plasma glucose (mg/dL)       111.0 (20.34)
   Sample storage time (years)           9.9 (1.25)
  Newborn characteristics                
   Gestational age at OGTT (weeks)       28.6 (1.37)
   Gestational age at delivery (weeks)   40.2 (1.15)
   Cord C-peptide (μg/L)                 1.1 (0.51)
   BW (g)                                3,667.6 (485.28)
   SS (mm)                               12.8 (2.74)
  -------------------------------------- ------------------

Data are means (SD) unless otherwise indicated.

Data and Sample Collection {#s4}
--------------------------

HAPO (conducted 2000--2006) methods have been described previously ([@B4]). Eligible women underwent a 75-g oral glucose tolerance test (OGTT) at 24--32 weeks\' gestation. Fasting plasma glucose (FPG) and 1-h plasma glucose were measured. Serum samples collected during the HAPO OGTT were stored at −80**°**C until the present metabolomics assays. Maternal height and weight and newborn BW and SS were measured by standard procedures with calibrated equipment. Gestational age was determined as previously described ([@B4]). Demographic and lifestyle characteristics were collected through questionnaire. Participants, caregivers, and HAPO staff remained blinded to glucose values unless glucose exceeded predefined levels. Unblinded participants were excluded.

Conventional Metabolite and Targeted Amino Acid and Acylcarnitine Analyses {#s5}
--------------------------------------------------------------------------

Conventional metabolites (lactate, triglycerides, β-hydroxybutyrate, glycerol) were measured as previously described ([@B8]) with the addition of nonesterified fatty acids (NEFAs), using reagents from Wako (Mountain View, CA). Targeted assays of amino acids and acylcarnitines (ACs) were performed by using stable isotope--labeled internal standards on an Acquity TQD system (Waters Corporation, Milford, MA) ([@B8]). In total, 63 conventional and targeted metabolites were analyzed to complement nontargeted gas chromatography/mass spectrometry (GC/MS) analyses to the fullest extent possible.

Nontargeted GC/MS Analyses {#s6}
--------------------------

Nontargeted assays designed to analyze the full range of metabolites present in serum were performed by GC/MS. Methanol, the extraction solvent, was spiked with a retention time locking internal standard of perdeuterated myristic acid. Extracts were dried, prepared by methoximation and trimethylsilylation ([@B8],[@B9]), and run on a 6890N GC/5975 Inert MS (Agilent Technologies, Santa Clara, CA). Programmed temperature vaporization in the inlet and postrun, midcolumn, hot back-flushing of the GC column minimized analyte decomposition, carryover, and fouling of GC and MS. Peaks were deconvoluted with AMDIS freeware ([@B10]) and parsed against the Fiehn GC/MS Metabolimics RTL library ([@B9]) with additions from our laboratory. Detected peak areas were log~2~ transformed for analysis. Manual curation included identification of coeluting groups of isomeric metabolites and selection of reliable peaks ([@B8]). Some fatty acids are methylated during sample preparation, and the methylated fatty acid was used in analyses. α- and β-Monopalmitin likely represented both endogenous metabolite and contaminant from sample preparation. In total, 84 GC/MS metabolites not assayed through targeted approaches were used for data analysis.

Batches of fasting and 1-h maternal serum sample pairs were constructed to balance field center, maternal glucose, and BMI and newborn outcomes across batches. Quality control pools were prepared with equal volumes from all maternal samples and prepared for analysis as described above. These pools were injected as first, middle, and last samples of each GC/MS run. Batches of equal size were run over 50 consecutive days.

Data Analysis {#s7}
-------------

GC/MS data were normalized to control technical variability attributable to batch and run order by using a mixture model approach in the R package metabomxtr ([@B11]). The mixture model can be viewed as a combination of a linear and logistic regression model, with the linear portion modeling quantifiable metabolite abundance and the logistic portion modeling detectability or lack thereof for a metabolite in a given sample. Given batch-specific detection thresholds, this approach is uniquely suited to GC/MS data. We specified separate mixture models for each metabolite by using quality control data, with metabolite level as the outcome, categorical batch variables in the logistic and linear model components, and log-transformed run order in the linear component. Variations in metabolite levels due to batch and run order were identified through the quality control data and then subtracted from analytical sample data to control technical noise for each metabolite.

Differences between maternal fasting and 1-h metabolite levels were evaluated with paired *t* tests for metabolites with ≥90% observed data. Associations between maternal fasting and 1-h glucose with metabolites at corresponding time points were evaluated using separate linear models, with metabolites as outcomes and glucose as predictors. For GC/MS metabolites undetectable in \>10% of samples, mixture models were used ([@B11]) similar to normalization. Linear models were also used to investigate associations between maternal metabolite predictors and newborn SS and BW outcomes. GC/MS metabolites undetectable in \>10% of samples were treated as four categories: one for undetected values and three for tertiles of normalized log~2~ peak areas. To model longitudinal associations for glucose and metabolites with detected values at both time points in ≥90% of mothers, we computed percent changes by dividing the difference between 1-h and fasting levels by the fasting level and repeated linear model analyses. Models were also examined for absolute differences between 1 h and fasting. All models included adjustment for field center, gestational age, maternal age, BMI, and mean arterial pressure at OGTT, newborn sex, and sample storage time. Adaptive Benjamini-Hochberg false discovery rate (FDR) correction was applied separately for targeted and nontargeted data ([@B12]).

Pathway analyses were conducted with MetaboAnalyst 3.0 ([@B13]) and its included set of human Kyoto Encyclopedia of Genes and Genomes pathways ([@B14]). Quantitative enrichment globaltest analysis ([@B15]) was used to identify maternal metabolites that are members of the same pathways and demonstrate collective associations with maternal fasting or 1-h glucose.

Because metabolites are not independent of one another but, rather, act in coordinated fashion, we conducted network analyses to complement individual metabolite analyses by simultaneously modeling metabolite correlations and phenotype associations. First, we constructed separate correlation networks for metabolites at fasting and 1 h. Nodes represented metabolites, and edges represented partial correlation of metabolite pairs at each time point with magnitude \>0.25 after adjustment for all covariates used in the aforementioned regression analyses. After correlation networks were constructed from all metabolites, we identified subnetworks comprising metabolites that demonstrated joint association with our phenotypes. To do this, we applied a subnetwork identification algorithm that incorporated node scores and edge weights based on phenotype associations to find the optimal scoring subnetwork for that phenotype ([@B16]).

We first identified subnetworks of maternal metabolites associated with maternal glucose at fasting and 1 h. Given the *P* value (p) for association between the metabolite and glucose, the node score was defined as S = −log(p) + log(0.10). This assigns high positive scores for *P* \< 0.10, modest positive scores for *P* close to but \<0.10, and increasingly negative scores for *P* \> 0.10. Edge weights were assigned by using algorithm defaults, giving higher weight to edges whose adjacent nodes had negative scores and low degree. Subnetworks associated with phenotype were determined by identifying connected sets of positively scoring nodes and evaluating whether uniting positive sets through negatively scoring nodes resulted in a positive sum of node scores. If so, the lowest weight edge path was used to connect nodes. To characterize local connectivity in networks, we applied spinglass community detection using the R package igraph ([@B17],[@B18]). Maternal glucose networks can be interpreted as sets of correlated metabolites that are all associated with fasting or 1-h glucose, with the highest correlation evident within spinglass communities.

Networks for maternal metabolites associated with both maternal glucose and newborn outcomes were identified by the same approach with a modified node score. Given *P* values p~m~ and p~n~ for a metabolite's association with maternal glucose and newborn outcome, respectively, we calculated an aggregate *P* value p~a~ for the maximum of p~m~ and p~n~ based on two random draws from a uniform distribution ([@B16]). We then set S = −log(p~a~) + log(0.10).

Random forest analyses were conducted using the R package party to identify maternal metabolites that improved prediction of newborn BW and SS beyond known risk factors maternal glucose and BMI. Random forests are data-driven learning methods designed for prediction ([@B19]), in this case applied to continuous newborn BW and SS outcomes. Overall model accuracy is measured as percent variation explained, and contributions of individual predictors are measured by variable importance. Given known high correlations among metabolites, we used conditional permutations to evaluate variable importance ([@B20]). This approach evaluates predictor contributions independent of other correlated predictors. Variable importance scores \>0 indicate higher percent variation explained when a predictor is included in the model. Variables with importance scores \<0 may decrease prediction accuracy. We examined random forest models as follows: M0 = maternal BMI at OGTT, gestational age at delivery, field center, and sample storage time; M1 = M0 + maternal glucose; M2 = M1 + highest scoring metabolite within N spinglass communities for the network; M3 = M1 + N metabolites with lowest p~a~ values; and M4 = M1 + metabolites with variable importance scores \>0 after running a model that included all metabolites with p~a~ \< 0.10.

Results {#s8}
=======

Study Population {#s9}
----------------

Study population characteristics are shown in [Table 1](#T1){ref-type="table"}. Mothers spanned the range of maternal BMI and glucose observed in the HAPO Study. Roughly equal numbers of males and females were represented among offspring.

Maternal Metabolites During the OGTT {#s10}
------------------------------------

Changes in multiple metabolites between fasting and 1 h were observed ([Fig. 1](#F1){ref-type="fig"} and [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1748/-/DC1)). All targeted amino acids, several long- and medium-chain fatty acids, and multiple products of lipid metabolism, including ACs, glycerol, and β-hydroxybutyrate, decreased after glucose ingestion. In contrast, triglycerides, carbohydrates, and metabolic intermediates, including pyruvate and citrate/isocitrate, increased.

![Volcano plot of maternal metabolites demonstrating differences from fasting to 1 h with FDR-adjusted *P* \< 0.05. The *y*-axis represents the negative log10 transformation of the nominal *P* value from paired *t* tests. The *x*-axis represents mean within-individual percent changes from fasting to 1 h. Points are colored according to metabolite class.](db151748f1){#F1}

Maternal Metabolites Associated With Maternal Glucose {#s11}
-----------------------------------------------------

A limited number of fasting metabolites were positively associated with FPG after FDR adjustment, including gluconeogenic substrates alanine and lactate as well as hexitols and fructose. Lauric acid, a medium-chain fatty acid, and palmitoleic acid and its AC were negatively associated with FPG ([Fig. 2](#F2){ref-type="fig"} and [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1748/-/DC1)).

![Heat map showing positive (red) and negative (blue) associations of maternal glucose and metabolites at fasting (lane A) and 1 h (lane B) during the OGTT as well as percent change associations from fasting to 1 h for maternal glucose and metabolites (lane C). All metabolites with FDR-adjusted *P* \< 0.05 for at least one time point or for percent change analyses are shown.](db151748f2){#F2}

At 1 h, more associations between metabolites and glucose were significant ([Fig. 2](#F2){ref-type="fig"} and [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1748/-/DC1)). Similar to fasting, positive associations were observed for 1-h alanine, lactate, and fructose. Positive associations were also observed for NEFA, β-hydroxybutyrate, triglycerides, glycerol, asparagine/aspartate, glutamine/glutamate, leucine/isoleucine, ornithine, phenylalanine, proline and serine, and multiple ACs and fatty acids. Also distinct were positive associations of gluconic acid, a marker of oxidative stress, and 2-hydroxybutyrate, a previously reported biomarker for insulin resistance ([@B21]), and a negative association of 1-h 1,5-anhydroglucitol.

Longitudinal analyses identified similar associations observed at individual time points with a few additions ([Fig. 2](#F2){ref-type="fig"} and [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1748/-/DC1)). Percent changes in citrulline and threonine exhibited significant associations with percent change in glucose. Analyses of absolute differences from fasting to 1 h were consistent with percent change associations (data not shown).

Pathway Analyses {#s12}
----------------

Pathway analyses identified multiple pathways related to amino acid, triglyceride, and sugar and carbohydrate metabolism whose metabolite members were jointly associated with FPG or 1-h glucose at corresponding time points ([Table 2](#T2){ref-type="table"}). There was substantial overlap in the pathways associated with glucose at the two time points, with a greater number of pathways demonstrating association at 1 h, including the tricarboxylic acid cycle (TCA) and metabolism of ketone bodies.

###### 

MetaboAnalyst pathway analysis results with FDR-adjusted *P* \< 0.05 for fasting and/or 1-h maternal metabolites

  Pathway name                                        No. of metabolites annotated to pathway   No. of measured metabolites   FDR-adjusted *P* value at fasting   FDR-adjusted *P* value at 1 h
  --------------------------------------------------- ----------------------------------------- ----------------------------- ----------------------------------- -------------------------------
  Amino acid metabolism                                                                                                                                           
   Selenoamino acid metabolism                        22                                        1                             3.6e-05                             0.00084
   Taurine and hypotaurine metabolism                 20                                        3                             4.7e-05                             0.0031
   Alanine, aspartate, glutamate metabolism           24                                        5                             4.7e-05                             6.2e-08
   Cysteine and methionine metabolism                 56                                        6                             0.0013                              0.00012
   Arginine and proline metabolism                    77                                        9                             0.0027                              1.6e-06
   Aminoacyl-tRNA biosynthesis                        75                                        15                            0.0044                              0.00013
   D-Glutamine and D-glutamate metabolism             11                                        1                             0.015                               1.2e-07
   Nitrogen metabolism                                39                                        6                             0.016                               3.7e-05
   Histidine metabolism                               44                                        3                             0.016                               7.3e-07
   Phenylalanine metabolism                           45                                        4                             0.016                               0.011
   Lysine biosynthesis                                32                                        3                             0.036                               0.00026
   Phenylalanine, tyrosine, tryptophan biosynthesis   27                                        2                             0.036                               0.026
   Glycine, serine, and threonine metabolism          48                                        7                             0.058                               0.0041
   D-Arginine and D-ornithine metabolism              8                                         2                             0.079                               0.015
   β-Alanine metabolism                               28                                        4                             0.12                                0.00053
   Cyanoamino acid metabolism                         16                                        3                             0.12                                0.0018
  Sugar and carbohydrate metabolism                                                                                                                               
   Galactose metabolism                               41                                        4                             4.5e-07                             1.6e-57
   Glycolysis or gluconeogenesis                      31                                        3                             4.5e-07                             9.8e-51
   Fructose and mannose metabolism                    48                                        1                             4.5e-07                             1.6e-20
   Pyruvate metabolism                                32                                        2                             3.1e-05                             7.3e-07
   Pentose phosphate pathway                          32                                        4                             9.2e-05                             2.2e-62
   Starch and sucrose metabolism                      50                                        3                             0.0031                              5.4e-45
   Amino sugar, nucleotide sugar metabolism           88                                        3                             0.0098                              6.6e-42
   Citrate cycle (TCA)                                20                                        3                             0.12                                0.00027
  Lipid metabolism                                                                                                                                                
   Fatty acid biosynthesis                            49                                        2                             0.00015                             0.0018
   Propanoate metabolism                              35                                        5                             0.0017                              5.9e-08
   Butanoate metabolism                               40                                        5                             0.015                               1.2e-12
   Glycerolipid metabolism                            32                                        3                             0.112                               9.0e-05
   Fatty acid metabolism                              50                                        2                             0.22                                0.00064
   Synthesis and degradation of ketone bodies         6                                         2                             0.33                                7.2e-09
   Sphingolipid metabolism                            25                                        1                             0.50                                0.012
  Vitamin metabolism                                                                                                                                              
   Nicotinate and nicotinamide metabolism             44                                        2                             0.0050                              9.0e-05
   Pantothenate and CoA biosynthesis                  27                                        3                             0.0098                              0.00081
   Vitamin B6 metabolism                              32                                        1                             0.025                               0.086
   Biotin metabolism                                  11                                        1                             0.073                               0.033
   Ascorbate and aldarate metabolism                  45                                        5                             0.12                                0.024
  Other                                                                                                                                                           
   Terpenoid backbone biosynthesis                    33                                        1                             0.025                               0.086
   Glutathione metabolism                             38                                        4                             0.050                               2.8e-06
   Porphyrin and chlorophyll metabolism               104                                       3                             0.05                                2.7e-05
   Glyoxylate and dicarboxylate metabolism            50                                        4                             0.11                                0.00076
   Sulfur metabolism                                  18                                        2                             0.74                                0.027

Maternal Metabolite Associations With Newborn Outcomes {#s13}
------------------------------------------------------

Although *P* values were not significant after FDR adjustment, several association trends between maternal metabolites and both newborn SS and BW were evident ([Fig. 3](#F3){ref-type="fig"} and [Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1748/-/DC1)). Maternal fasting and 1-h triglycerides, fasting AC C4-OH, 1-h fructose, gluconic acid, and hexitols were positively associated. Maternal fasting 1,5-anhydroglucitol, lysine, and pentonic acids were negatively associated.

![Heat map showing positive (red) and negative (blue) associations of maternal metabolites at fasting and 1 h and percent change with newborn SS (lanes A--C, respectively) and BW (lanes D--F, respectively). Glucose in this figure refers to the original HAPO OGTT maternal glucose measurements. All metabolites with a nominal *P* \< 0.05 for at least one time point or in percent change analyses are shown.](db151748f3){#F3}

Other metabolites demonstrated unique association trends with either outcome. Fasting maternal tyrosine, glycerol 1-phosphate, and linoleic and stearic acids; 1-h hypoxanthine and malonic acid; and both fasting and 1-h AC C8, AC C8:1-OH/C6:1-DC, and glucuronic acid were negatively associated with newborn SS. Fasting β-hydroxybutyrate was positively associated with SS. Other ACs demonstrated several associations in both directions with SS at either time point or longitudinally. For newborn BW, positive associations included 1-h dihydroxybutanoic acid, threonine, and citric acid. Fasting palmitic acid was negatively associated with BW. Percent changes in AC C16:2, glycerol 1-phosphate, threonine, urea, aminomalonic acid, fructose, and several fatty acids were positively associated with BW.

Maternal Glucose Networks {#s14}
-------------------------

Network analyses were conducted to contextualize individual metabolite associations and describe joint associations on behalf of correlated metabolites. Several metabolites demonstrating associations in separate models were part of identified networks, whereas others were excluded because they do not correlate with other metabolites. Some metabolites were included that did not reach individual statistical significance. The network associated with glucose at fasting includes three spinglass communities of carbohydrates and organic acids, amino acids, and ACs and fatty acids. The 1-h network is substantially larger and, again, sorted primarily into communities of carbohydrates and organic acids, amino acids, and ACs ([Fig. 4](#F4){ref-type="fig"}).

![Subnetworks of maternal metabolites associated with maternal fasting and 1-h glucose. Nodes represent metabolites, and edges represent partial correlation \>0.25 for metabolite pairs. Nodes are sized according to node score--based *P* values, with larger nodes corresponding to higher scores. Nodes are colored according to metabolite class. Gray shading identifies spinglass communities within the subnetworks. Direction of association is noted by color shading in the nodes. Positive associations are darker, and negative associations are lighter. *A*: The subnetwork of maternal fasting metabolites associated with maternal FPG. *B*: The subnetwork of maternal 1-h metabolites associated with maternal 1-h plasma glucose (1PG). AA, amino acid; CHO, carbohydrate; FA, fatty acid; GC, glycolysis; Misc, miscellaneous.](db151748f4){#F4}

Maternal Glucose and Newborn Outcome Networks {#s15}
---------------------------------------------

Networks for metabolites associated with maternal glucose and newborn outcomes were smaller with more granular spinglass communities at both fasting and 1 h ([Fig. 5](#F5){ref-type="fig"}). Unlike the networks associated with maternal glucose alone, amino acids were largely absent from networks incorporating associations with newborn outcomes. Also striking was the transition of ACs from primarily negative associations with fasting glucose to largely positive associations with 1-h glucose and the larger size and stronger associations of this community with newborn SS compared with BW ([Fig. 5](#F5){ref-type="fig"}).

![Subnetworks of maternal metabolites associated with maternal glucose and newborn outcomes. Nodes represent metabolites, and edges represent partial correlation \>0.25 for metabolite pairs. Nodes are sized according to node score based on aggregate *P* values, with larger nodes corresponding to higher scores. Nodes are colored according to metabolite class. Gray shading identifies spinglass communities within the subnetworks. Direction of association for maternal glucose and newborn outcome is noted by color shading in the left and right sides of the nodes, respectively. Positive associations are darker, and negative associations are lighter. *A*: The subnetwork of maternal fasting metabolites associated with maternal FPG and newborn SS. *B*: The subnetwork of maternal fasting metabolites associated with maternal FPG and newborn BW. *C*: The subnetwork of maternal 1-h metabolites associated with maternal 1PG and newborn SS. *D*: The subnetwork of maternal 1-h metabolites associated with maternal 1PG and newborn BW. 1PG, 1-h plasma glucose; AA, amino acid; CHO, carbohydrate; FA, fatty acid; GC, glycolysis; Misc, miscellaneous.](db151748f5){#F5}

Random Forest Analyses {#s16}
----------------------

To determine whether metabolites associated with maternal glucose contribute to the prediction of newborn BW and SS beyond traditional risk factors, including glucose, random forest analyses were performed ([Table 3](#T3){ref-type="table"} and [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1748/-/DC1)). Model M1, which includes maternal glucose at either fasting or 1 h, explained higher overall percent variation for both newborn outcomes compared with model M0, which includes maternal BMI and other baseline covariates. This reflects the well-substantiated role of maternal glucose in newborn size outcomes. As seen in [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1748/-/DC1), the relative contribution of glucose as a predictor of newborn outcomes (measured by conditional variable importance) decreased in models M2, M3, and M4 compared with M1 as additional metabolites were included. This decrease suggests that maternal metabolites that correlate with glucose account in part for the effect of glucose on these newborn outcomes. Importantly, in models M2, M3, and M4 where metabolites associated with both glucose and newborn outcomes are included as predictors, the percent variation explained is consistently higher than in M1 for both BW and SS. Taken together, the decrease in variable importance for glucose in M2, M3, and M4 and the increase in percent overall variation explained by these models indicate that metabolites that are part of the broad-scale changes associated with maternal glycemia are independent contributors to newborn size outcomes.

###### 

Overall percent variation explained for random forest models predicting newborn size outcomes

                                                      Percent variation explained                        
  --------------------------------------------------- ----------------------------- ------ ------ ------ -------
  Maternal FPG and fasting metabolites---newborn SS   3.99                          6.03   7.59   8.13   10.08
  Maternal FPG and fasting metabolites---newborn BW   3.02                          4.35   8.01   7.47   7.16
  Maternal 1-h PG and 1-h metabolites---newborn SS    3.99                          5.35   7.08   6.98   8.52
  Maternal 1-h PG and 1-h metabolites---newborn BW    3.02                          7.07   8.49   7.89   9.22

M0, baseline model including maternal BMI, gestational age at delivery, field center, and sample storage time; M1, M0 + maternal glucose at fasting or 1 h; M2, M3, and M4, M1 + metabolites selected according to strategies described in [[research design and methods]{.smallcaps}](#s2){ref-type="sec"}. Individual metabolites are listed in [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1748/-/DC1).

Discussion {#s17}
==========

Maternal metabolism during pregnancy differs from the pregravid state due to metabolic adaptations to meet the mother's and growing fetus's energy needs ([@B22]--[@B24]). Pregnancy has been described as accelerated starvation during fasting to meet fetal demands for glucose, amino acids, and other nutrients and facilitated anabolism following nutrient ingestion to allow repletion of maternal reserves ([@B22]). For example, women in the third trimester of pregnancy exhibit a larger decrease in total free fatty acids and an increase in triglycerides compared with the nongravid state following glucose ingestion ([@B5],[@B22]). The current study characterized the maternal metabolome in women with glucose levels across the range observed in a population-based study of women who underwent an OGTT at ∼28 weeks\' gestation ([@B4]). To date, studies characterizing the metabolome of pregnant women have largely been limited in size and have focused on fasting women with GDM compared with healthy pregnant women ([@B25]). To our knowledge, the current study is the largest and first in pregnant women that examined two OGTT time points to identify maternal metabolites associated with glucose as a quantitative trait.

Prior studies examining the effect of glucose ingestion on the metabolome have been limited to nonpregnant populations ([@B26]--[@B32]). Similar to those studies, we demonstrated a glucose-induced decrease in multiple metabolites, including glycerol, β-hydroxybutyrate, NEFA, medium- and long-chain fatty acids, ACs, and amino acids. Pyruvate increased as did lactate after glucose ingestion; the latter has been previously reported ([@B26]). Previous findings with Krebs cycle intermediates have varied ([@B26],[@B32]). We observed an increase in circulating citrate/isocitrate but no change in lactate, fumarate, and malate. Thus, despite pregnancy-induced insulin resistance and attendant changes in maternal metabolism, glucose-stimulated insulin secretion in pregnancy inhibits lipolysis, proteolysis, and ketogenesis and stimulates glycolysis similar to nonpregnant populations.

To date, metabolomic studies during pregnancy have focused largely on women with GDM, a state of relative insulin insufficiency due to inadequate maternal β-cell compensation for pregnancy-induced insulin resistance ([@B33]). Differences among the metabolomes between women without and with GDM have been reported, but few metabolites have demonstrated consistent changes across studies, likely due to small sample sizes and various technologies and study designs ([@B25]). Total and individual free fatty acids have been reported as either higher or both higher and lower during the second or third trimester in women with GDM and/or an impaired glucose challenge test ([@B25],[@B34]--[@B36]). Previous studies of amino acid levels in women with GDM have been inconsistent ([@B25]). We identified many metabolites and metabolic pathways associated with maternal glucose at 28 weeks\' gestation independent of maternal BMI. In the fasting state, a limited number of metabolites were positively associated with maternal glucose, most notably lactate and alanine. A potential explanation for the higher levels of these gluconeogenic substrates in the setting of maternal hyperglycemia is inefficient glucose utilization and relative mitochondrial inefficiency with diversion of glucose to alanine and lactate as opposed to entering the TCA. This finding is consistent with the observation that alanine, lactate, and organic acids are higher early in pregnancy (∼16 weeks\' gestation) in women subsequently given a diagnosis of GDM ([@B37]). After glucose ingestion, many more metabolites were associated with maternal glucose, including a positive association of many amino acids and ACs. This is consistent with blunted insulin-induced inhibition of proteolysis and lipolysis in women with higher glucose and suggests that metabolic changes during pregnancy are not limited to GDM.

A unique aspect of this study was the availability of fetal phenotypes in addition to maternal phenotype and metabolomic data. Association of maternal glucose and triglyceride levels with BW and fetal adiposity has been demonstrated ([@B3],[@B4],[@B38]--[@B42]). Maternal fatty acids increase during pregnancy, are transported across the placenta, and contribute to fetal growth ([@B6]), whereas levels of amino acids, which are important for fetal protein accretion and growth, fall ([@B23],[@B43]). Maternal fatty acids and glycerol have been shown to be associated with BW and fat mass in mothers with GDM but not in control subjects ([@B39],[@B44]). Findings with amino acids have been inconsistent; some found no association with BW of maternal amino acids late in gestation, whereas others showed positive associations of maternal serine, lysine, proline, ornithine, and arginine and a negative association of methionine ([@B45],[@B46]). Others found positive associations of aspartate, alanine, ornithine, and arginine levels at 25 weeks\' gestation with BW ([@B47]). In the current study, individual maternal metabolites failed to demonstrate FDR-adjusted associations with newborn BW or SS. Fasting and 1-h triglycerides were nominally positively associated with BW and SS, and fasting levels of tyrosine and several fatty acids were nominally negatively associated with SS or BW. The reasons for the difference between the current results and earlier studies are not known, but the earlier studies were small with different study designs.

Recognizing that metabolites likely act in concert rather than individually, we performed network analyses to identify correlated metabolites associated with both maternal and fetal phenotypes. These network studies identified interrelated groups of maternal metabolites that collectively demonstrate consistent, often subtle, associations with both maternal glucose and newborn outcomes. At fasting, clusters of fatty acids and the carnitine esters of long- and medium-chain fatty acids were associated with maternal fasting glucose and newborn SS and/or BW. At 1 h, a cluster of ACs of long- and medium-chain fatty acids together with the ketone body β-hydroxybutyrate demonstrated an association with maternal 1-h glucose and both SS and BW. Different from the fasting state, clusters of sugars and metabolic intermediates at 1 h were also associated with maternal and newborn phenotypes. These include potential products of the polyol pathway, fructose and hexitols. The polyol pathway increases susceptibility to oxidative stress and contributes to diabetic complications ([@B48]). Of note, amino acid clusters were associated with maternal fasting or 1-h glucose alone but not with newborn phenotypes.

The Pedersen hypothesis states that higher transplacental transport of glucose and resulting fetal insulin secretion in the setting of maternal hyperglycemia contribute to macrosomia ([@B5]). The HAPO Study confirmed this hypothesis ([@B4]). Freinkel ([@B5]) modified the hypothesis to suggest that nutrients in addition to glucose also contribute to fetal growth and fat accretion in the setting of maternal hyperglycemia. We used random forest analysis to confirm Freinkel's modification of the Pedersen hypothesis by identifying multiple metabolites associated with maternal glucose that contribute to newborn BW and SS independent of maternal glucose and BMI. As seen in [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1748/-/DC1), a broad array of maternal metabolites makes some contribution to BW and/or SS. In the fasting state, this includes a number of lipid-related metabolites (fatty acids, triglycerides, glycerol 1-phosphate, ACs of medium-chain fatty acids), uric acid, and sugars (hexitols, myoinositol). Of note, lysine is the only amino acid in the fasting state that contributes to newborn size in these analyses. Previously, lysine levels helped to explain variability in the development of GDM ([@B49]), and higher levels of lysine have been demonstrated in some studies of women with GDM ([@B45],[@B46],[@B50]). At 1 h, a similar pattern was evident with lipid-related metabolites (β-hydroxybutyrate among others), sugars (fructose, hexitols, disaccharides, maltose), products of carbohydrate metabolism (citrate/isocitrate, lactate), and amino acids (methionine, phenylalanine), which all contributed to newborn outcomes. Together, these analyses demonstrate that beyond glucose, additional metabolites associated with glucose are independent contributors to newborn size at birth and, in aggregate, may have the potential to predict fetal size at birth.

The current study had several strengths. It is the largest to date to examine the association of maternal metabolic traits with maternal metabolites and the first in pregnant women to examine associations across the full range of glucose and associations of metabolites with glucose at both fasting and 1 h following a glucose load. Because pregnancy has been described as a state of accelerated starvation and facilitated anabolism, the examination of metabolites in both the fasting and the postprandial state is important. This is also the first metabolomic study to include mother-newborn dyads to allow for the examination of associations between the maternal metabolome and newborn outcomes and the identification of metabolites associated with glucose important for newborn size at birth. One limitation is the use of nontargeted assays that are not strictly quantitative. These assays allow unbiased examination of metabolite-phenotype associations, but findings of interest will ultimately require the development of targeted assays for confirmation. Moreover, the network and random forest analyses will require replication in independent studies.

In conclusion, we demonstrate broad-scale association of metabolites with either maternal fasting or 1-h glucose by using population-based data and provide new insight into metabolic changes characteristic of maternal hyperglycemia. We also found evidence for a role of maternal triglycerides, fatty acids, and their metabolites together with sugars and metabolic intermediates in newborn outcomes, whereas random forest analyses suggest that these and other metabolites are independent contributors to newborn BW and SS. Further studies relating these findings to the fetal metabolome will provide additional insight into mechanisms underlying fetal size at birth.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-1748/-/DC1>.
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